Abstract
1 Pharmacokinetic investigations were carried out in a group of 32 ambulant normal male volunteers in order to determine the effect of age and smoking on steady-state plasma levels of pindolol and propranolol. There were four groups of 8: young non-smokers (YNS), young smokers (YS), old non-smokers (ONS) and old smokers (OS). Each subject received, in a randomized cross-over sequence, 5 mg pindolol and 80 mg propranolol three times daily for 2 days with an interval of at least 14 days between the two treatment periods. 2 Neither age nor smoking was shown to have any influence on the time to reach a peak plasma level after pindolol or propranolol. Age, on the other hand, significantly increased the peak plasma levels and the areas under the plasma concentration time curves, and decreased the elimination rate constants, the differences between the age groups being more pronounced for propranolol than for pindolol. No effect of smoking on these parameters was observed. 3 Differences were found between pindolol and propranolol in respect of time to reach a peak plasma level, peak plasma levels and area under the plasma concentration time curves in the groups ONS and YS when related to the YNS control group. Changes observed (with the exception of the time to reach a peak level) tended to be less for pindolol and were considered to be of little clinical relevance.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aellig W. H. beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers. Br J Clin Pharmacol. 1976 Apr;3(2):251–257. doi: 10.1111/j.1365-2125.1976.tb00600.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gugler R., Herold W., Dengler H. J. Pharmacokinetics of pindolol in man. Eur J Clin Pharmacol. 1974;7(1):17–24. doi: 10.1007/BF00614385. [DOI] [PubMed] [Google Scholar]
- Hill R. C., Turner P. Preliminary investigations of a new beta-adrenoceptive receptor blocking drug, LB46, in man. Br J Pharmacol. 1969 Jun;36(2):368–372. doi: 10.1111/j.1476-5381.1969.tb09511.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mackichan J. J., Pyszczynski D. R., Jusko W. J. Dose-dependent disposition of oral propranolol in normal subjects. Biopharm Drug Dispos. 1980 Apr-Jun;1(4):159–166. doi: 10.1002/bdd.2510010403. [DOI] [PubMed] [Google Scholar]
- Meier J., Nüesch E. Pindolol, a beta-adrenoceptor blocking agent with a negligible first-pass effect. Br J Clin Pharmacol. 1977 Jun;4(3):371–372. doi: 10.1111/j.1365-2125.1977.tb00726.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Morgan T. O., Louis W. J., Dawborn J. K., Doyle A. E. The use of prindolol (Visken) in the treatment of hypertension. Med J Aust. 1972 Aug 5;2(6):309–312. doi: 10.5694/j.1326-5377.1972.tb47306.x. [DOI] [PubMed] [Google Scholar]
- Nation R. L., Peng G. W., Chiou W. L. High-pressure liquid chromatographic method for the simultaneous quantitative analysis of propranolol and 4-hydroxypropranolol in plasma. J Chromatogr. 1978 May 1;145(3):429–436. doi: 10.1016/s0378-4347(00)81372-9. [DOI] [PubMed] [Google Scholar]
- Pacha W. L. A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine. Experientia. 1969 Aug 15;25(8):802–803. doi: 10.1007/BF01897885. [DOI] [PubMed] [Google Scholar]
- Vestal R. E., Wood A. J., Branch R. A., Shand D. G., Wilkinson G. R. Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther. 1979 Jul;26(1):8–15. doi: 10.1002/cpt19792618. [DOI] [PubMed] [Google Scholar]
- Vestal R. E., Wood A. J., Shand D. G. Reduced beta-adrenoceptor sensitivity in the elderly. Clin Pharmacol Ther. 1979 Aug;26(2):181–186. doi: 10.1002/cpt1979262181. [DOI] [PubMed] [Google Scholar]